73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Genfit
Open
SectorHealthcare
5.21 -0.67
Overview
Share price change
24h
Min
5.05
Max
5.245
Income | -10M |
|---|---|
Sales | 36M |
Profit margin | -28.017 |
Employees | 188 |
EBITDA | 955K |
Recommendations | Buy |
|---|---|
12 Months Forecast | +59.95% upside |
Market Cap | 265M |
|---|---|
Previous open | 5.88 |
Previous close | 5.21 |
News Sentiment
By Acuity
16%
84%
13 / 374 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Genfit Chart
Past performance is not a reliable indicator of future results.
Related News
Genfit Forecast
Price Target
By TipRanks
59.95% upside
12 Months Forecast
Average 8.397 EUR 59.95%
High 8.4 EUR
Low 8.4 EUR
Based on 1 Wall Street analysts offering 12 month price targets forGenfit - Dist in the last 3 months.
Sentiment
By Acuity
13 / 374 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Live chat